Carpal tunnel syndrome (CTS) has been defined as a compression neuropathy of the median nerve at the wrist. Carpal tunnel syndrome, the most common repetitive motion disorder, is on the rise in the United States. As health care costs continue to increase, the need for effective treatment of CTS becomes of paramount importance. Currently, there is no gold standard treatment for CTS that has proven to effectively and consistently treat the symptoms of CTS. The FleXtend™ is a product which proponents claim relieves the signs and symptoms associated with CTS. Twenty-six hands were randomly divided into either a control group or FleXtend™ treatment group. Eight hands, already under the care of a physician, were assigned to a medical intervention group. Each hand was measured for grip strength, a visual analog pain scale, Phalen's Test and Reverse Phalen's Test, and A Self-Administered Questionnaire for the Assessment of Severity of Symptoms and Functional Status in Carpal Tunnel Syndrome. The FleXtend™ group then received an intervention for four weeks. All groups were retested at four and eight weeks. The results of this study indicated that there was no statistical significance between the groups for grip strength, visual analog pain scale, Phalen's Test, and Reverse Phalen's Test. However, there was a statistically significant decrease in symptoms and increase in function as measured by the survey between the groups, demonstrating that the FleXtend™ may be an effective treatment option for CTS.
Files are restricted to Pacific University. Sign in to view.